HRSA-26-087: Strategies to Link, Engage, and Retain Men with HIV in Care: Evaluation Provider
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Health Resources and Services Administration notices from 2026.
Health Resources and Services Administration offered grants of up to $1.3 million to nonprofits, colleges and universities, state and local governments and tribes. It expected to make one award worth $1.3 million in total. Applications closed on July 8, 2026.
From the official notice on Grants.gov, last changed June 5, 2026. Checked November 7, 2026.
- Award ceiling$1.3 million
- Total funding$1.3 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | June 5, 2026 |
|---|---|
| Deadline | July 8, 2026 |
| Archived by Grants.gov | September 30, 2026 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments and tribes.
All 11 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
Is this a realistic fit?
- Past Special Projects of National Significance awards averaged $1.2 million; this notice allows up to $1.3 million per award.
- No cost sharing or match is required.
What the grant funds
The purpose of this funding opportunity is to award one cooperative agreement recipient to serve as the Evaluation Provider (EP). This funding opportunity has a companion funding opportunity to fund an Implementation Technical Assistance Provider (ITAP). The two recipients will work collaboratively, but conduct distinct activities that support the overall initiative. The proposed initiative will be comprised of one Evaluation Provider (EP), one Implementation Technical Assistance Provider (ITAP) funded as a separate cooperative agreement, and up to eight (8) implementation sites sub-awarded by the ITAP. This initiative will use implementation science to adapt, implement, and evaluate the implementation of interventions that serve men with HIV who are not consistently engaged in care or experiencing barriers to staying in care This initiative directly aligns with Ryan White Program 2030 (RWP2030), which is a renewed vision for the Ryan White HIV/AIDS Program (RWHAP). Building on the foundation of the RWHAP and the Ending the HIV Epidemic in the U.S. initiative, the RWP2030 framework is designed to sustain high-quality care and treatment for people currently receiving services through the RWHAP while expanding efforts to identify and engage individuals with HIV who are undiagnosed or out-of-care. The funded Evaluation Provider (EP) will lead a multi-site evaluation of the project and will provide evaluation-specific technical assistance (TA) to the implementation sites. The evaluation activities that the EP will conduct will draw from frameworks and approaches developed in the field of implementation science, including HAB"s Implementation Science Framework. The initiative emphasizes: 1) rapid adaptation, implementation, and evaluation; 2) implementation at a broad scale to produce generalizable findings; 3) public release of dissemination products based on human-centered design and adult learning principles, which foregrounds sustainability, rapid dissemination of findings, and replication of best practices.
Who has won Special Projects of National Significance grants before
From fiscal 2021 to 2025, Special Projects of National Significance (93.928) awarded $104 million across 85 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fenway Community Health Center, Inc. | Massachusetts | 2 | $20.1 million |
| National Alliance of State & Territorial AIDS Directors | District of Columbia | 1 | $13.9 million |
| Jsi Research & Training Institute Inc | Massachusetts | 6 | $13.3 million |
| Corporation for Supportive Housing | New York | 1 | $13.2 million |
| The Regents of the University of California, San Francisco | California | 4 | $6.2 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-26-087 still open?
No. It closed on July 8, 2026.
Who can apply for Strategies to Link, Engage, and Retain Men with HIV in Care: Evaluation Provider?
Health Resources and Services Administration accepted applications from nonprofits, colleges and universities, state and local governments and tribes.
What is the deadline for Strategies to Link, Engage, and Retain Men with HIV in Care: Evaluation Provider?
Closed July 8, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.3 million each. About $1.3 million in total for one award.
Who has won Special Projects of National Significance grants before?
The largest recipients over five fiscal years were Fenway Community Health Center, Inc., National Alliance of State & Territorial AIDS Directors, Jsi Research & Training Institute Inc. The program made 85 awards worth $104 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)